Provided herein are engineered antibodies that comprise a modified IgA2 heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitutions or deletions in a constant region of an IgA2 domain that modify naturally occurring glycosylation site(s). Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.

The present invention generally relates to chimeric receptors comprising an extracellular domain comprising a mutated Fc domain. The invention also relates to transduced immune cells expressing the chimeric receptors of the invention and/or nucleic acid molecules encoding the chimeric receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules encoding the chimeric receptors, and antibodies capable of binding to the chimeric receptors.

The present disclosure relates to methods of purifying immunoglobulin G (IgG) and other proteins, such as albumin, from plasma or a fraction thereof using an affinity chromatography resin comprising a ligand capable of specifically binding to a CH3 domain of human IgG. The present disclosure also relates to formulation and uses of plasma protein product produced from the method.

The invention provides improved vector composition comprising chimeric antigen receptor for adoptive T cell therapies.

The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-, including for example without limitation, bispecific MIGIS-/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS- and CD3.

The present disclosure relates to methods of re-oxidizing an antigen-binding protein.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Novel nucleic acid compositions, vector systems, modified cells, isolated peptides, isolated nucleic acid sequences and pharmaceutical compositions that encode or express T cell receptor components directed against Jchain are provided herein. These novel components may be used to enhance an immune response in a subject diagnosed with a B cell associated disease or condition. Associated methods for treating such subjects are also provided herein.

The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.